{"id":"NCT00794664","sponsor":"Kastle Therapeutics, LLC","briefTitle":"Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis","officialTitle":"A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-05","completion":"2010-10","firstPosted":"2008-11-20","resultsPosted":"2013-03-21","lastUpdate":"2016-09-09"},"enrollment":58,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia","Coronary Heart Disease"],"interventions":[{"type":"DRUG","name":"Mipomersen","otherNames":["ISIS 301012","Mipomersen sodium","Kynamroâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Mipomersen","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in treating severely hypercholesterolemic patients who are on a maximally tolerated lipid-lowering regimen and who are not on apheresis.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point","timeFrame":"Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET) up to week 28","effectByArm":[{"arm":"Placebo","deltaMin":12.5,"sd":46.87},{"arm":"Mipomersen","deltaMin":-35.9,"sd":24.71}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":2},"locations":{"siteCount":27,"countries":["United States","Canada","Czechia","Germany","South Africa","United Kingdom"]},"refs":{"pmids":["23152839","27578134","25614280"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Injection site erythema","Injection site pain","Injection site pruritus","Injection site haematoma","Injection site swelling"]}}